UBS initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $30 price target The firm believes Summit’s lead program, ivonescimab, could become the new standard of care in front-line non-small cell lung cancer with a greater than $7B peak sales opportunity, or $11B unadjusted, while the stock is pricing in about $5B, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Revolution Medicines, Summit Therapeutics enter clinical collaboration
- Revolution Medicines, Summit Therapeutics team to evaluate RAS inhibitors
- Summit Therapeutics’ Promising Clinical Trials and Market Potential Drive Buy Rating
- Summit Therapeutics Signs Sublease with Ascendis Pharma
- Summit Therapeutics Holds Successful 2025 Annual Meeting